Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008
about
Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosisFirst evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countriesCorrelation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility resultsDiscordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence CountryIntegrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes.Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United StatesDetermination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometryEpidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China.Challenges and controversies in defining totally drug-resistant tuberculosis.Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugsDiagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs.Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase
P2860
Q28087770-D3F84F2B-2E39-4957-9281-13FA99384FFCQ28534345-5347523A-39E5-4189-ACD5-2309D002E669Q28540488-AB99FA23-DA74-4969-B086-1BA1FFCD9E96Q28551469-79C08DA5-FB10-4F1F-A6BB-93003395433DQ30300560-64622E88-1263-4001-9DDF-78A0C469592AQ33703407-82BE7F45-9B49-4DE6-AB46-282D128EA60CQ35960935-C479CDC1-2B17-4000-8E41-23AE7855FFA5Q36082638-E5169772-5C5B-4DAD-B42A-DE4C3C6B9466Q36247548-93C197F5-CF6A-4A99-B161-BB8CD24ACFEEQ36574273-D791CAC7-1D2A-4AAB-8C35-881B5ACEC9A2Q37544293-41FA056B-7237-44C0-9083-75BF34B16AD8Q38059860-5346F0DC-9E87-4C3F-953F-7A0A4B9FFB72Q58603045-73BD78DB-6BC0-4FC0-A66D-52C15F7C40F8
P2860
Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Performance of tuberculosis dr ...... laboratories from 1994 to 2008
@ast
Performance of tuberculosis dr ...... laboratories from 1994 to 2008
@en
type
label
Performance of tuberculosis dr ...... laboratories from 1994 to 2008
@ast
Performance of tuberculosis dr ...... laboratories from 1994 to 2008
@en
prefLabel
Performance of tuberculosis dr ...... laboratories from 1994 to 2008
@ast
Performance of tuberculosis dr ...... laboratories from 1994 to 2008
@en
P2093
P2860
P356
P1476
Performance of tuberculosis dr ...... laboratories from 1994 to 2008
@en
P2093
Beverly Metchock
J Rex Astles
John C Ridderhof
Michael F Iademarco
Pawan K Angra
Thomas H Taylor
P2860
P304
P356
10.1128/JCM.06479-11
P407
P577
2012-02-01T00:00:00Z